ArticleNature2016
Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism.
Article in Nature, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06219031 (A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer), which is not on this map. Cited by 661 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer
Who cites it
661 citing papers in PubMed, 988 citations in OpenAlex.
- The LXRβ/NF-κB axis reprograms CAR-T cells to resist exhaustion in the tumor microenvironment.Oncoimmunology · 2026Article
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Article
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- A PD-L1 Nanobody-Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC-I.Exploration (Beijing, China) · 2026Article
- Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Integrative multi-omics analysis identifies LIPA as a prognostic hub and ferroptosis regulator in lung adenocarcinoma.Molecular and cellular biochemistry · 2026Article
- Distinct effector functions and synergy of CAR mRNA-engineered T cells and macrophages in the clearance of CD19Journal of advanced research · 2026Article
- Inhibition of the lipocalin-2-phosphatidylserine axis restores natural killer cell immune surveillance.Cell reports. Medicine · 2026Article
- In vivo CRISPR screens identify dual functions of DNMT3A in mediating tumor immune evasion.Nature communications · 2026Article
- The multifaceted landscape of T cell exhaustion in organ transplantation: From molecular mechanisms (epigenetics, transcription, metabolism) to induction strategies.Genes & diseases · 2026Review
- Review
- Nanozyme-Mediated Cellular and Microenvironmental Metabolic Reprogramming for Boosting Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Targeting PID1 generates oxysterols to switch macrophage cell fates for improved antitumor immunity.Nature cancer · 2026Article
- A general strategy towards multicolour fluorogenic peptides for wash-free bioassays.Nature chemistry · 2026Article
- Review
- Association Between Total Cholesterol and In-Hospital Mortality Among First-Episode Acute Coronary Syndrome Patients: Multilevel Analysis from NCVD-ACS Registry.Healthcare (Basel, Switzerland) · 2026Article
- Review
- Metabolic rewiring of the dendritic cell-T cell axis: tumour-derived barriers and therapeutic opportunities.Experimental & molecular medicine · 2026Review
- The interplay between lipid metabolism, cancer progression and anti-cancer immunity.Experimental & molecular medicine · 2026Review
601 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 9 institutions in 2 countries.
Funding
Abstract
CD8(+) T cells have a central role in antitumour immunity, but their activity is suppressed in the tumour microenvironment. Reactivating the cytotoxicity of CD8(+) T cells is of great clinical interest in cancer immunotherapy. Here we report a new mechanism by which the antitumour response of mouse CD8(+) T cells can be potentiated by modulating cholesterol metabolism. Inhibiting cholesterol esterification in T cells by genetic ablation or pharmacological inhibition of ACAT1, a key cholesterol esterification enzyme, led to potentiated effector function and enhanced proliferation of CD8(+) but not CD4(+) T cells. This is due to the increase in the plasma membrane cholesterol level of CD8(+) T cells, which causes enhanced T-cell receptor clustering and signalling as well as more efficient formation of the immunological synapse. ACAT1-deficient CD8(+) T cells were better than wild-type CD8(+) T cells at controlling melanoma growth and metastasis in mice. We used the ACAT inhibitor avasimibe, which was previously tested in clinical trials for treating atherosclerosis and showed a good human safety profile, to treat melanoma in mice and observed a good antitumour effect. A combined therapy of avasimibe plus an anti-PD-1 antibody showed better efficacy than monotherapies in controlling tumour progression. ACAT1, an established target for atherosclerosis, is therefore also a potential target for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.